Northwest Biotherapeutics enters $5M convertible note with 11% interest, 24-month maturity

NORTHWEST BIOTHERAPEUTICS INC

Company entered $5,000,000 convertible note with an unrelated shareholder on Oct 31, 2024.
Note matures in 24 months with no payments due until maturity; interest at 11% per annum.
Holder can convert into common stock at $0.30/share or non-dilutive financial instrument priced at $50,000.
Proceeds will be used for ongoing business operations; customary default provisions apply.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.